Projects View

Novartis to Invest $256 Million to Expand Biopharmaceutical Manufacturing Facility in Singapore

Specifications:

Name:

Novartis to Invest $256 Million to Expand Biopharmaceutical Manufacturing Facility in Singapore

Location:

Singapore

Company:

Novartis

Estimated Cost:

$256 Million

Source:

https://www.novartis.com

Introduction:

Novartis has announced the expansion of its biopharmaceutical manufacturing plant in Singapore.

Features:

With an investment of US$256 million, Novartis aims to enhance manufacturing productivity, operational efficiency, and workforce skills through the deployment of advanced digital and automation solutions. The expanded facility will focus on producing therapeutic antibody drugs, contributing to the delivery of innovative treatments to patients around the world.

Set to be operational by early 2026, this new facility in Singapore is a strategic move that will strengthen biopharmaceutical manufacturing and supply chains across Asia. It will also boost local capabilities and provide significant upskilling opportunities for talent in Singapore.

This expansion will not only enhance the skills of the existing Novartis workforce but also create 100 new high-skilled job opportunities, promoting growth within the local life sciences sector. Recognizing the importance of talent development, Novartis plans to bring in new team members and provide extensive training to help current employees succeed in a highly digitalized and automated environment.